Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance

Tumors employ multiple mechanisms to evade immune surveillance. One mechanism is tumor-induced myelopoiesis, whereby the expansion of immunosuppressive myeloid cells can impair tumor immunity. As myeloid cells and conventional dendritic cells (cDCs) are derived from the same progenitors, we postulated that myelopoiesis might impact cDC development. The cDC subset, cDC1, which includes human CD141+ DCs and mouse CD103+ DCs, supports anti-tumor immunity by stimulating CD8+ T-cell responses. Here, to understand how cDC1 development changes during tumor progression, we investigated cDC bone marrow progenitors. We found localized breast and pancreatic cancers induce systemic decreases in cDC1s and their progenitors. Mechanistically, tumor-produced granulocyte-stimulating factor downregulates interferon regulatory factor-8 in cDC progenitors, and thus results in reduced cDC1 development. Tumor-induced reductions in cDC1 development impair anti-tumor CD8+ T-cell responses and correlate with poor patient outcomes. These data suggest immune surveillance can be impaired by tumor-induced alterations in cDC development.Tumors escape the immune system through many mechanisms. Here the authors show that certain tumors inhibit anti-tumor immunity by stopping the production of conventional dendritic cells (cDCs) in the bone marrow, therefore depleting the pool of cDCs available to present antigen to CD8+ T cells.

• Publication year

  2018

• Venue

  Nature Communications

• Publication date

  2018-03-28

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/s41467-018-03600-6PMID 29593283PMCID 5871846
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.

  2017cited by this paper
• The Granulocyte Progenitor Stage Is a Key Target of IRF8-Mediated Regulation of Myeloid-Derived Suppressor Cell Production

  2017cited by this paper
• Lineage specification of human dendritic cell is marked by expression of the transcriptionl factor IRF8 in HSCs and MPPs

  2017cited by this paper
• Mapping the human DC lineage through the integration of high-dimensional techniques

  2017cited by this paper
• Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses.

  2017cited by this paper
• Dendritic cells in cancer: the role revisited.

  2017cited by this paper
• Targeting neoantigens to augment antitumour immunity

  2017cited by this paper
• Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.

  2016cited by this paper
• Visualization of immediate immune responses to pioneer metastatic cells in the lung

  2016cited by this paper
• Leading Edge Review The Basis of Oncoimmunology

  2016cited by this paper
• XCR1+ dendritic cells promote memory CD8+ T cell recall upon secondary infections with Listeria monocytogenes or certain viruses

  2016cited by this paper
• Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

  2016cited by this paper
• Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma.

  2016cited by this paper
• Targeting Focal Adhesion Kinase Renders Pancreatic Cancers Responsive to Checkpoint Immunotherapy

  2016cited by this paper
• Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.

  2016cited by this paper
• Human dendritic cells (DCs) are derived from distinct circulating precursors that are precommitted to become CD1c+ or CD141+ DCs

  2016cited by this paper
• Targeting the programmed cell death-1 pathway in breast and ovarian cancer

  2016cited by this paper
• Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells.

  2016cited by this paper
• Functions of Murine Dendritic Cells.

  2016cited by this paper
• Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy.

  2016cited by this paper
• Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition.

  2016cited by this paper
• Neutrophils in cancer: neutral no more

  2016cited by this paper
• Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected.

  2015cited by this paper
• Identification of cDC1- and cDC2-committed DC progenitors reveals early lineage priming at the common DC progenitor stage in the bone marrow

  2015cited by this paper
• Transcriptional Heterogeneity and Lineage Commitment in Myeloid Progenitors.

  2015cited by this paper
• Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

  2015cited by this paper
• IL17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis

  2015cited by this paper
• Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils

  2015cited by this paper
• Batf3 maintains Irf8 autoactivation for commitment of a CD8α+ cDC clonogenic progenitor

  2015cited by this paper
• Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells.

  2014cited by this paper
• Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity.

  2014cited by this paper
• PD-1 blockade induces responses by inhibiting adaptive immune resistance

  2014cited by this paper
• Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer

  2013cited by this paper
• Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis.

  2013cited by this paper
• Inactivation of tumor-specific CD8+ CTLs by tumor-infiltrating tolerogenic dendritic cells

  2013cited by this paper
• Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells.

  2012cited by this paper
• IRF-8 extinguishes neutrophil production and promotes dendritic cell lineage commitment in both myeloid and lymphoid mouse progenitors.

  2012cited by this paper
• Zbtb46 expression distinguishes classical dendritic cells and their committed progenitors from other immune lineages

  2012cited by this paper
• Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth

  2012cited by this paper
• Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer.

  2012cited by this paper
• IRF-8 controls melanoma progression by regulating the cross talk between cancer and immune cells within the tumor microenvironment.

  2012cited by this paper
• Human Tissues Contain CD141hi Cross-Presenting Dendritic Cells with Functional Homology to Mouse CD103+ Nonlymphoid Dendritic Cells

  2012cited by this paper
• Coordinated regulation of myeloid cells by tumours

  2012cited by this paper
• Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis.

  2012cited by this paper
• Anti‐IL‐6 receptor mAb eliminates myeloid‐derived suppressor cells and inhibits tumor growth by enhancing T‐cell responses

  2012cited by this paper
• Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.

  2011cited by this paper
• Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma

  2010cited by this paper
• Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.

  2010cited by this paper
• Peripheral CD103+ dendritic cells form a unified subset developmentally related to CD8α+ conventional dendritic cells

  2010cited by this paper
• Inaugural Article: Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes

  2010cited by this paper
• Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes

  2010cited by this paper
• The origin and development of nonlymphoid tissue CD103+ DCs

  2009cited by this paper
• Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists

  2008cited by this paper
• Batf3 Deficiency Reveals a Critical Role for CD8α+ Dendritic Cells in Cytotoxic T Cell Immunity

  2008cited by this paper
• Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources

  2008cited by this paper
• Differential Antigen Processing by Dendritic Cell Subsets in Vivo

  2007cited by this paper
• Development of plasmacytoid and conventional dendritic cell subtypes from single precursor cells derived in vitro and in vivo

  2007cited by this paper
• A Clonogenic Bone Marrow Progenitor Specific for Macrophages and Dendritic Cells

  2006cited by this paper
• CXCR4 Regulates Growth of Both Primary and Metastatic Breast Cancer

  2004cited by this paper
• Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity.

  2003cited by this paper
• ICSBP/IRF-8 retrovirus transduction rescues dendritic cell development in vitro.

  2003cited by this paper
• Essential role for ICSBP in the in vivo development of murine CD8alpha + dendritic cells.

  2003cited by this paper
• ICSBP Is Essential for the Development of Mouse Type I Interferon-producing Cells and for the Generation and Activation of CD8α+ Dendritic Cells

  2002cited by this paper
• CD4 and CD8 Expression by Dendritic Cell Subtypes in Mouse Thymus and Spleen1

  2000cited by this paper
• A clonogenic common myeloid progenitor that gives rise to all myeloid lineages

  2000cited by this paper
• Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation.

  1999cited by this paper
• Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection.

  1995cited by this paper
• Inhibition of tumor growth by elimination of granulocytes

  1995cited by this paper
• Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease

  1992cited by this paper

• Heterocellular crosstalk and architecture of the pancreatic tumour microenvironment.

  2026cites this paper
• From Cell Death and Activation to Paralysis: Dysregulated Conventional Dendritic Cells in SIRS, Sepsis and Major Trauma Promote Immunosuppression

  2026cites this paper
• Macrophage Extracellular Traps in Immunity and Cancer.

  2026cites this paper
• Combined Flt3L and CD40 agonism restores dendritic cell-driven T cell immunity in pancreatic cancer.

  2025cites this paper
• Transcriptional and chromatin accessibility landscapes of hematopoiesis in a mouse model of breast cancer.

  2025cites this paper
• Dendritic cells instruct T cell anti-tumor immunity and immunotherapy response

  2025cites this paper
• CD4+ T helper 2 cell–macrophage crosstalk induces IL-24–mediated breast cancer suppression

  2025cites this paper
• Cross-priming in cancer immunology and immunotherapy

  2025cites this paper
• Harnessing Notch Signaling to Enhance the Generation and Functionality of Human Conventional Type I Dendritic Cells for Cancer Immunotherapy Applications.

  2025cites this paper
• Tumour Evolution Driving Genome Instability, Immune Interactions, and Response to Radiotherapy

  2025cites this paper
• Ms4a7 expression in cDC1s determines cross-presentation and antitumor immunity.

  2025cites this paper
• Cancer immune evasion, immunoediting and intratumour heterogeneity

  2025cites this paper
• Triple-negative breast cancer modifies the systemic immune landscape and alters neutrophil functionality

  2025cites this paper
• The Infectious Clue: Linking Bacterial Infections to Underlying Malignancies

  2025cites this paper
• The Making of a cDC1: Precision Programming of Progenitor Potential

  2025cites this paper
• An OMV‐Based Nanovaccine as Antigen Presentation Signal Enhancer for Cancer Immunotherapy

  2025cites this paper
• The Impact of Malaria-Induced Neutrophil Subset Shift and a Link to Burkitt Lymphoma

  2025cites this paper
• A Combinatorial Effect of Immune Checkpoint Inhibitors and CD40 Agonistic Antibody in Murine Pancreatic Cancer Model

  2025cites this paper
• COUP-TFII-mediated reprogramming of the vascular endothelium counteracts tumor immune evasion

  2025cites this paper
• Protocol for specific induction of apoptosis or necroptosis in established murine tumors

  2025cites this paper
• Dendritic cell maturation in cancer

  2025cites this paper
• Cancer vaccines: current status and future directions

  2025cites this paper
• Enhancing cDC1-mediated anti-tumor immunity limits tumor progression and potentiates anti-PD-1 therapy in intrahepatic cholangiocarcinoma

  2025cites this paper
• Research Progress of Radiotherapy Combined With Immunotherapy for Breast Cancer: Mechanism Exploration and Clinical Translation.

  2025cites this paper
• Flt3L enhances clonal diversification and selective expansion of intratumoral CD8+ T cells while differentiating into effector-like cells.

  2024cites this paper
• Dendritic Cell and Regulatory T Cell numbers in relation to Breast Cancer Progression and Metastasis

  2024cites this paper
• Genetics and biology of pancreatic ductal adenocarcinoma

  2024cites this paper
• The XCL1-Mediated DNA Vaccine Targeting Type 1 Conventional Dendritic Cells Combined with Gemcitabine and Anti-PD1 Antibody Induces Potent Antitumor Immunity in a Mouse Lung Cancer Model

  2024cites this paper
• Comparative prognostic value of tumor volume in IOIO and IOTKI treatment for metastatic renal cancer.

  2024cites this paper
• Understanding the role of TNFR2 signaling in the tumor microenvironment of breast cancer

  2024cites this paper
• Interleukin-1α release during necrotic-like cell death generates myeloid-driven immunosuppression that restricts anti-tumor immunity.

  2024cites this paper
• Extramedullary hematopoiesis in cancer

  2024cites this paper
• The multiple roles of interferon regulatory factor family in health and disease

  2024cites this paper
• The role of dendritic cells in cancer immunity and therapeutic strategies.

  2024cites this paper
• The mediating effect of circulating inflammatory proteins on the relationship between gut microbiota and FD: a bidirectional Mendelian randomization study

  2024cites this paper
• Downregulation of IRF8 in alveolar macrophages by G-CSF promotes metastatic tumor progression

  2024cites this paper
• Future of Dendritic Cell-Based Approaches in Pancreatic Cancer.

  2024cites this paper
• Trafficking circuit of CD8+ T cells between the intestine and bone marrow governs antitumour immunity

  2024cites this paper
• Anatomy of a superenhancer.

  2024cites this paper
• Barriers and opportunities in pancreatic cancer immunotherapy

  2024cites this paper
• In vivo dendritic cell reprogramming for cancer immunotherapy

  2024cites this paper
• A Self‐Delivery Nanodrug Simultaneously Inhibits COX‐2/PGE2 Mediated Inflammation and Downregulates PD‐L1 to Boost Photoimmunotherapy

  2024cites this paper
• The crosstalk between lung cancer and the bone marrow niche fuels emergency myelopoiesis

  2024cites this paper
• TNFR1 signaling promotes pancreatic tumor growth by limiting dendritic cell number and function

  2024cites this paper
• Lipid Nanoparticle‐mRNA Engineered Dendritic Cell Based Adoptive Cell Therapy Enhances Cancer Immune Response

  2024cites this paper
• A cancer immunotherapy modality based on dendritic cell reprogramming in vivo

  2024cites this paper
• Effector Functions of Dendritic Cells in Cancer: Role of Cytotoxicity and Growth Inhibition.

  2024cites this paper
• The cross-talk between the macro and micro-environment in precursor lesions of pancreatic cancer leads to new and promising circulating biomarkers

  2024cites this paper
• Neutrophils in Cancer immunotherapy: friends or foes?

  2024cites this paper
• Engineering immune response to regulate cardiovascular disease and cancer.

  2024cites this paper
• Recent Findings on Therapeutic Cancer Vaccines: An Updated Review

  2024cites this paper
• mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends

  2024cites this paper
• Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept

  2024cites this paper
• Multimodal immune phenotyping reveals microbial-T cell interactions that shape pancreatic cancer

  2024cites this paper
• Made to order: emergency myelopoiesis and demand-adapted innate immune cell production

  2024cites this paper
• Mobilization and activation of tumor-infiltrating dendritic cells inhibits lymph node metastasis in intrahepatic cholangiocarcinoma

  2024cites this paper
• Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target

  2024cites this paper
• Analysis of single nuclear chromatin accessibility reveals unique myeloid populations in human pancreatic ductal adenocarcinoma

  2024cites this paper
• The complexity of immune evasion mechanisms throughout the metastatic cascade

  2024influential citation
• Comprehensive analysis of disulfidptosis-related genes: a prognosis model construction and tumor microenvironment characterization in clear cell renal cell carcinoma

  2024cites this paper
• Strategy and application of manipulating DCs chemotaxis in disease treatment and vaccine design.

  2023cites this paper
• The role of CXCL12 axis in pancreatic cancer: New biomarkers and potential targets

  2023cites this paper
• Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment

  2023cites this paper
• Longitudinal analysis of DC subsets in patients with ovarian cancer: Implications for immunotherapy

  2023cites this paper
• Impact of Recombinant Granulocyte Colony-Stimulating Factor During Neoadjuvant Therapy on Outcomes of Resected Pancreatic Cancer.

  2023cites this paper
• The show and tell of cross-presentation.

  2023cites this paper
• Antigen cross-presentation by dendritic cells: A critical axis in cancer immunotherapy.

  2023cites this paper
• Dysregulation of systemic soluble immune checkpoints in early breast cancer is attenuated following administration of neoadjuvant chemotherapy and is associated with recovery of CD27, CD28, CD40, CD80, ICOS and GITR and substantially increased levels of PD-L1, LAG-3 and TIM-3

  2023cites this paper
• Lymph node metastasis and tumor-educated immune tolerance: Potential therapeutic targets against distant metastasis.

  2023cites this paper
• Dendritic cells as shepherds of T cell immunity in cancer.

  2023cites this paper
• Tumor-derived interleukin-1α and leukemia inhibitory factor promote extramedullary hematopoiesis

  2023cites this paper
• Interferon-induced lysosomal membrane permeabilization and death cause cDC1-deserts in tumors

  2023cites this paper
• PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer

  2023cites this paper
• Approaches to the development of the dendritic cell and neoantigen-based antitumor vaccines

  2023cites this paper
• Targeting cGAS/STING signaling-mediated myeloid immune cell dysfunction in TIME

  2023cites this paper
• IL-6 selectively suppresses cDC1 specification via C/EBPβ

  2023influential citation
• Carcinogen exposure enhances cancer immunogenicity by blocking the development of an immunosuppressive tumor microenvironment

  2023cites this paper
• Dendritic cell maturation in the tumor microenvironment

  2023cites this paper
• Tumor-derived GCSF Alters Tumor and Systemic Immune System Cell Subset Composition and Signaling

  2023cites this paper
• Harnessing dendritic cell diversity in cancer immunotherapy.

  2023cites this paper
• Systemic Alterations in Type-2 Conventional Dendritic Cells Leads to Impaired Tumor Immunity in Pancreatic Cancer.

  2023cites this paper
• Ultrasound Responsive Nanovaccine Armed with Engineered Cancer Cell Membrane and RNA to Prevent Foreseeable Metastasis

  2023cites this paper
• Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses.

  2023cites this paper
• Addition of losartan to FOLFIRINOX and chemoradiation reduces immunosuppression-associated genes, Tregs and FOXP3+ cancer cells in locally advanced pancreatic cancer.

  2023cites this paper
• Dendritic cell-based immunotherapy: a potential player in oral cancer therapeutics.

  2023cites this paper
• Impaired function of dendritic cells within the tumor microenvironment

  2023cites this paper
• Conventional type 1 dendritic cells (cDC1) in cancer immunity

  2023cites this paper
• CARD9 deficiency promotes pancreatic cancer growth by blocking dendritic cell maturation via SLC6A8-mediated creatine transport

  2023cites this paper
• Breast cancer remotely imposes a myeloid bias on haematopoietic stem cells by reprogramming the bone marrow niche

  2023cites this paper
• Immune cellular components and signaling pathways in the tumor microenvironment.

  2022cites this paper
• Facts and Hopes in Immunotherapy of Pancreatic Cancer.

  2022cites this paper
• Exercise-induced engagement of the IL-15/IL-15Rα axis promotes anti-tumor immunity in pancreatic cancer.

  2022cites this paper
• Think global but act local: Tuning the Dendritic cell response in cancer.

  2022cites this paper
• Dendritic Cells metabolism - a strategic path to improve antitumoral DC vaccination.

  2022cites this paper
• Nanocarrier Co-formulation for Delivery of a TLR7 Agonist plus an Immunogenic Cell Death Stimulus Triggers Effective Pancreatic Cancer Chemo-immunotherapy.

  2022cites this paper
• Distinct myeloid antigen-presenting cells dictate differential fates of tumor-specific CD8+ T cells in pancreatic cancer

  2022cites this paper
• Genome-wide expression reveals potential biomarkers in breast cancer bone metastasis

  2022cites this paper
• Human dendritic cells in cancer

  2022cites this paper
• Multifunctional Lipid Bilayer Nanocarriers for Cancer Immunotherapy in Heterogeneous Tumor Microenvironments, Combining Immunogenic Cell Death Stimuli with Immune Modulatory Drugs.

  2022cites this paper
• Hematologic dysfunction in cancer: Mechanisms, effects on antitumor immunity, and roles in disease progression

  2022influential citation